MarketFriction

Alembic Pharmaceuticals Ltd

NSE APLLTD · BSE 533573 · Pharmaceuticals
₹815.25 -1.24%
NSE close2026-10-01
52 week range635.80 - 998.00
Market cap₹16,934 Cr.
P/E22.7
Price band 20% Delivery 63.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150
Expenses1,3871,3641,2571,3251,4091,4331,4981,4301,5941,5851,6201,818
Operating Profit208266260237239260271281316292228332
OPM %13%16%17%15%15%15%15%16%17%16%12%15%
Other Income1034230101468-27215
Interest161511131922252424232328
Depreciation686969697170697476808998
Profit before tax135185183157180178192190224162119222
Tax %-1%2%3%14%15%23%18%19%18%18%-70%22%
Net Profit137180178135153138157154184132202172
EPS in Rs6.959.189.076.857.807.047.987.859.406.7610.318.80
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,1663,1053,1313,9354,6065,3935,3065,6536,2296,6727,3457,784
Expenses2,1592,4902,4883,0613,3833,9134,4324,9705,2965,6646,2246,617
Operating Profit1,0076156438741,2231,4808746829321,0081,1211,167
OPM %32%20%21%22%27%27%16%12%15%15%15%15%
Other Income7279-398756-22856-14-1
Interest553182716185056799498
Depreciation7283105115157183287275273279319342
Profit before tax9365295417491,0001,368625355632707694726
Tax %23%23%22%21%20%19%17%4%3%18%3%
Net Profit7204034135838011,146521342616582671690
EPS in Rs38.2021.3921.8931.0043.9758.3326.5017.4031.3329.6834.3335.27
Dividend Payout %9%19%18%18%23%24%38%46%35%37%35%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth9%6%9%14%
Compounded Profit Growth0%-9%28%26%
Stock Price CAGR3%2%3%-4%
Return on Equity16%11%13%13%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital383838383838393939393939
Reserves8471,5601,8652,1822,6813,1825,0285,1984,3314,7795,1525,636
Borrowings264114897081,1281,7475847177225131,2581,430
Other Liabilities4937186981,0139311,0221,0581,1671,0901,1141,3251,658
Total Liabilities1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763
Fixed Assets5477087999931,1581,5521,7881,7982,3982,5472,5243,081
CWIP83933961,0101,5511,8462,1832,304601524837683
Investments287504249182361189693127141
Other Assets1,0091,5411,4441,8962,0192,5732,5022,9023,0873,2814,2854,858
Total Assets1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1729483293128124491,46355272480388783
Cash from Investing Activity-256-307-486-884-756-731-840-372-448-321-568-506
Cash from Financing Activity87-224-12950359155-597-217-262-438444-164
Net Cash Flow3417-286-69115-12726-371445-37113
Free Cash Flow-52647348-49549-285804128282487-466290
CFO/OP60%114%73%70%112%56%115%77%115%88%16%79%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days644040614569245668607773
Inventory Days196266269302356417431406315350466462
Days Payable166264213313237220194178145157179154
Cash Conversion Cycle94429651164266261283237253363381
Working Capital Days323661692450737477888787
ROCE %38%66%29%22%23%24%26%11%7%13%13%13%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters69.61%69.61%69.61%69.61%69.61%69.61%69.67%69.68%69.74%69.74%69.74%69.87%
FIIs4.51%4.52%4.46%4.32%3.94%4.17%3.94%3.96%4.04%4.23%4.26%4.17%
DIIs14.22%14.51%15.39%15.47%16.05%16.05%16.43%16.46%16.30%16.17%16.17%15.93%
Public11.67%11.36%10.54%10.61%10.38%10.17%9.96%9.91%9.92%9.84%9.83%10.00%
No. of Shareholders89,55285,21276,56774,82991,42993,94491,33689,01389,96987,00086,43286,796

Fundamentals

Market Cap₹ 16,934 Cr.
Current Price₹ 862
Stock P/E22.7
Book Value₹ 289
ROCE12.6 %
ROE13.4 %
Dividend Yield1.39 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)14%
Compounded Profit Growth (TTM)26%
Consolidated figures.
Valuation
Market capRs 16,025 Cr
Enterprise valueRs 17,252 Cr
P/E (TTM)23.11x
Price to book2.82x
Price to sales2.06x
EV / EBITDA14.80x
EV / EBIT20.95x
EV / sales2.22x
Price to cash flow20.47x
Earnings yield4.33%
Dividend yield1.47%
P/E, 3-year average27.36x
P/B, 3-year average3.28x
P/E, 5-year average27.72x
P/B, 5-year average2.97x
Profitability
Operating margin (excl. other income)15.26%
Operating margin (incl. other income)15.06%
EBITDA margin14.98%
Pre-tax margin9.32%
Net profit margin8.91%
Net margin, latest quarter8.05%
ROE12.42%
ROCE11.62%
ROA8.16%
ROE, 3-year average12.49%
ROCE, 3-year average12.72%
ROA, 3-year average8.71%
ROE, 5-year average10.94%
ROCE, 5-year average11.32%
ROA, 5-year average7.76%
ROIC (approx.)11.53%
Tax rate3.33%
Other income / net worth-0.26%
Growth
Sales growth (latest year)10.08%
Profit growth (latest year)15.66%
Sales CAGR, 3 years9.12%
Sales CAGR, 5 years6.37%
Profit CAGR, 3 years25.42%
Profit CAGR, 5 years-10.06%
Sales growth QoQ16.35%
Profit growth QoQ-14.62%
Sales growth YoY (latest quarter)25.66%
Profit growth YoY (latest quarter)12.11%
Per share
EPS (TTM)Rs 35.28
EPS (latest year)Rs 34.33
EPS (latest quarter)Rs 8.80
EPS, 3-year averageRs 31.78
EPS, 5-year averageRs 27.85
Book value per shareRs 288.70
Sales per shareRs 396.00
Cash flow per shareRs 39.82
Free cash flow per shareRs 14.75
Dividend per share (latest year)Rs 12.00
Dividend per share, 3-year averageRs 11.33
Dividend per share, 5-year averageRs 10.40
Dividends
Dividend payout34.95%
Dividend payout, 3-year average35.71%
Dividend payout, 5-year average38.17%
Efficiency
Asset turnover0.84x
Fixed asset turnover2.38x
Inventory turnover1.05x
Inventory days348 days
Debtor days73 days
Debtors turnover5.01x
Creditor days154 days
Cash conversion cycle381 days
Working capital days87 days
Leverage
Total debtRs 1,430 Cr
Cash and bankRs 203 Cr
Net debtRs 1,227 Cr
Debt to equity0.25x
Net debt / EBITDA1.05x
Interest coverage8.43x
Current ratio (filing 2026-03-31)1.75x
Quick ratio (filing 2026-03-31)0.78x
Trade payables (filing 2026-03-31)Rs 835 Cr
Owners' fund to total sources64.76%
Debt to assets16.32%
Cash flow
Cash from Operating Activity (latest year)Rs 783 Cr
Cash from Investing Activity (latest year)Rs -506 Cr
Cash from Financing Activity (latest year)Rs -164 Cr
Net Cash Flow (latest year)Rs 113 Cr
Free cash flow (latest year)Rs 290 Cr
FCFE (approx.: FCF + change in debt)Rs 462 Cr
Cash from ops / profit, 5 years1.08x
Sales to cash flow9.38x
Statement figures
Net sales (TTM)Rs 7,784 Cr
Net sales (latest year)Rs 7,345 Cr
Sales (latest quarter)Rs 2,150 Cr
Operating profit excl. other income (latest year)Rs 1,121 Cr
Operating profit (latest quarter)Rs 332 Cr
Other income (TTM)Rs -1 Cr
EBITDA (TTM)Rs 1,166 Cr
PBDT (TTM)Rs 1,068 Cr
Profit before tax (TTM)Rs 726 Cr
Tax (latest year)Rs 23 Cr
Net profit (TTM)Rs 693 Cr
Net profit (latest year)Rs 675 Cr
Net profit (latest quarter)Rs 173 Cr
Depreciation (TTM)Rs 342 Cr
Depreciation (latest quarter)Rs 98 Cr
Interest (TTM)Rs 98 Cr
Cost of goods sold (latest year)Rs 2,632 Cr
Total expenditure (latest year)Rs 6,224 Cr
Total income (latest year)Rs 7,330 Cr
Share capitalRs 39 Cr
ReservesRs 5,636 Cr
Shareholders' fundsRs 5,675 Cr
Total assetsRs 8,763 Cr
Net blockRs 3,081 Cr
Capital work in progressRs 683 Cr
InvestmentsRs 141 Cr
ReceivablesRs 1,466 Cr
InventoryRs 2,511 Cr
Other liabilitiesRs 1,658 Cr
Shares outstanding (crore)19.66
Ownership
Promoter holding69.87% (+0.19 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 23.1 is at the 38th percentile of its own 9.4-year range (median 24.5, low 12.4, high 58.6).
P/B 2.82 is at the 15th percentile (median 3.86).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodAPLLTDNifty 50Difference
1 week-4.1%-2.8% -1.3 pts
1 month-3.4%-6.8% +3.4 pts
3 months-1.0%-7.6% +6.6 pts
6 months+22.9%+0.4% +22.5 pts
1 year-11.6%-9.9% -1.6 pts
2 years-30.0%-13.6% -16.5 pts
3 years+3.9%+14.2% -10.2 pts
5 years+3.4%+27.9% -24.5 pts
38 mutual fund schemes hold about ₹1,457 Cr. Over three months 10 bought more and 9 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Kotak Small Cap Fund1.45%286 -3%
ICICI Pru Healthcare Fund-2.48%173 -3%
DSP Small Cap Fund0.58%125 -7%
Axis Small Cap Fund0.39%122 -4%
DSP Healthcare Fund3.14%120 -6%
DSP ELSS Tax Saver Fund0.72%120 +2%
DSP Aggressive Hybrid Fund0.57%67 +2%
ICICI Pru Manufacturing Fund0.86%61 +66%
DSP Midcap Fund0.22%47 -47%
ICICI Pru Small Cap Fund0.44%43 -1%
ICICI Pru Small Cap Fund0.44%42 -1%
Abakkus Small Cap Fund1.48%41 -11%
UTI Large & Mid Cap Fund0.60%39 +30%
UTI Aggressive Hybrid Fund0.55%37 +35%
UTI MNC Fund1.19%33 +13%
UTI Healthcare Fund1.16%17 -7%
UTI Retirement Fund0.35%17 +39%
Motilal Oswal Nifty Microcap 250 Index Fund0.48%12 -4%
DSP Multi Cap Fund0.35%11 -1%
HDFC Retirement Fund-Hybrid-Equity Plan0.65%10 +3%
ICICI Pru Children's Fund0.70%10 +1%
DSP Equity Savings Fund(M0.25%8 +5%
DSP Value Fund0.23%5 -12%
The Wealth Company Mid Cap Fund2.20%4 +100%
The Wealth Company Multi Asset Allocation Fund1.08%2 -8%

Red flags

F-score 6 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹2,150 Cr +25.7% vs Jun 2025. Net profit ₹172 Cr +11.7%.
Against our estimate for Jun 2026: sales +16.8%, profit +0.3% in line. Our estimate for Sep 2026: sales Rs 2,197 Cr, profit Rs 194 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-29Dividend - Rs 12 Per Share
2025-07-29Dividend - Rs 11 Per Share
2024-07-15Dividend - Rs 11 Per Share
2023-07-28Dividend - Rs 8 Per Share
2022-08-17Interim Dividend - Rs 10 Per Share
2021-07-19 Annual General Meeting/Dividend - Rs 14 Per Share
2020-03-16 Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share
2019-07-18 Annual General Meeting/Dividend Rs 5.50/-
2018-07-18 Annual General Meeting/Dividend- Rs 4 Per Share (Purpose Revised)
2017-07-11 Annual General Meeting/Dividend -Rs 4/- Per Share
2016-07-20 Annual General Meeting/Dividend - Rs 4/- Per Share
2015-07-22Annual General Meeting/ Dividend - Rs 3.50/- Per Share
2014-07-17Annual General Meeting / Dividend - Rs 3/- Per Share
2013-07-29Annual General Meeting And Dividend Rs.2.50 Per Share
2012-07-31Annual General Meeting / Dividend Rs 1.40 Per Share
DateTypeWhat it says
2026-09-18Concall / analyst meetSchedule of meet
2026-09-16UpdatesUpdate on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.
2026-09-11General UpdatesSuccessful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited s Bioequivalence Facility in Vadodara, Gujarat
2026-09-07General UpdatesGeneral Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Who...
2026-08-27Concall / analyst meetSchedule of meet
2026-08-27Concall / analyst meetSchedule of meet
2026-08-20Change in Company Secretary/Change in Company Secretary/Compliance Officer
2026-08-10ResignationResignation of Director/KMP/SMP
2026-08-10ResignationResignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2026.
2026-08-10Concall / analyst meetTranscript
2026-08-06Shareholder meetingVoting results.
2026-08-05Shareholder meetingProceedings of Annual General Meeting held on August 05, 2026
2026-08-04Concall / analyst meetLink of Recording
2026-08-04Press Release (Revised)A revised press release dated August 04, 2026, titled "Revised Press Release on the Unaudited Financial Results for the quarter ended30th June, 2026."...
2026-08-04Press ReleaseA press release dated August 04, 2026, titled "Press Release on the Unaudited Financial Results for the quarter ended30th June, 2026.".
2026-08-04Investor PresentationInvestor Presentation
2026-08-04Board meeting outcomeAlembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-04Board meeting outcomeOutcome of Board Meeting held on August 04, 2026.
2026-07-28Press ReleaseA press release dated July 28, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets, 1 mg and 2 mg.".
2026-07-27Concall / analyst meetSchedule of Post Results Conference Call on Tuesday, 4th August, 2026
2026-07-18Press ReleaseA press release dated July 18, 2026, titled "Alembic Pharmaceuticals Limiteds Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olapa...
2026-07-13General UpdatesGeneral Updates Disclsoure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2026-07-10UpdatesSpecimen Copy Of The Letter Sent To The Shareholders Under Regulation 36(1)(b) Of SEBI LODR.
2026-07-10Record DateRecord date for the purpose of Dividend is 29-Jul-2026.
2026-07-10Shareholder meetingNotice of 16th Annual General Meeting to be held on August 05, 2026 at 4:00 p.m. IST.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd (APLLTD) has a market capitalisation of Rs 16,934 Cr. at the 2026-10-01 close.

What is the P/E ratio of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd trades at a P/E of 22.7 on trailing twelve-month profit, at the 2026-10-01 close.

What were Alembic Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Alembic Pharmaceuticals Ltd sales was Rs 2,150 Cr (+25.7% vs Jun 2025) and net profit was Rs 172 Cr.

What is the 52-week high and low of Alembic Pharmaceuticals Ltd?

The 52-week high is Rs 998.00 and the 52-week low is Rs 635.80.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03